medjouel.com Study Non Stop
Related Articles
A substance known as LNA043, derived from angiopoietin-like 3, is generating significant interest due to its potential in promoting cartilage regeneration. This scientific breakthrough introduces new prospects in treating this degenerative joint condition, instilling hope for the millions worldwide who suffer from osteoarthritis. Insights are shared by Laurent Grange, a rheumatologist at CHU Grenoble-Alpes (Isère).
It aids in cartilage regeneration, the tissue that safeguards the ends of bones and deteriorates in cases of osteoarthritis. With anti-inflammatory properties, it operates by stimulating tissue synthesis and inhibiting degradation at the level of specialized cells known as chondrocytes.
While current medications provide relief from symptoms, they do not halt cartilage degradation. Hence, the interest in LNA043, which has the potential to restore it. However, caution is advised as the findings published in December 2022 in Nature Medicine are based on a study involving only 28 patients. Prudence is necessary, given past instances of highly promising molecules falling short.
Its safety and efficacy won’t be confirmed until 2027-2030. Subsequently, several more years will be required before it can be brought to the market. Though the timeline is lengthy, LNA043 is presently one of the most advanced molecules in this field.
